Home Behandelprotocollen APL Richtlijnen en literatuur


Klik HIER voor de concept behandelrichtlijn AML (2018) van de HOVON Leukemie werkgroep.

AIDA 2000 protocol: Guidelines for the treatment of acute promyelocytic leukemia. – Avvisati G. et al. – GIMEMA version 4.1 – April 2001.  


  1. Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275-1291. doi: 10.1182/blood-2017-09-801498
  2. Cicconi L et al. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia 2018; 32(8): 1671-1678. e-pub ahead of print 2018/07/22; doi: 10.1038/s41375-018-0219-5
  3. Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 129:424-447.
  4. Arber D.A. et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 127:2391-2405.
  5. Montesinos P. et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome and prognostic factors. Blood. 2009 113:775-783.
  6. Estey E. et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006 107:3469-3473.
  7. Sanz M.A. et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 96:1247-1253.
  8. Lo-Coco et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111-121. 

Ga terug naar de APL homepage of lees meer over APL: Ga terug naar de algemene homepage Behandelprotocollen